Sandoz Confirms Launch Of Humira Rival In Canada

Introduction Of Hyrimoz Comes As Other Adalimumab Biosimilars Expected

Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.

Canada Flag Rocket Clouds Launch
Sandoz has confirmed launch of its adalimumab biosimilar in Canada • Source: Shutterstock

Sandoz Canada has confirmed that it has launched its Hyrimoz (adalimumab) biosimilar rival to Humira, after it and other Canadian biosimilars players set their sights on a mid-February launch.

Last year, Sandoz had suggested that it would launch Hyrimoz around 15 February, while Fresenius Kabi had also pointed to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.